Suchergebnisse - "Vasconcelos, Joana C"

PubPharm (39)

1

National prevalence of vision impairment and blindness and associated risk factors in adults aged 40 years and older with known or undiagnosed diabetes : results from the SMART-India cross-sectional study

enthalten in: The Lancet. Global health | 2024

von Gurudas, S. | Vasconcelos, J. | Prevost, A. | +38

2

Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA) : a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial

enthalten in: Lancet (London, England) | 2024

von Cope, A. | Jasenecova, M. | Vasconcelos, J. | +70

3

Burden of undiagnosed and suboptimally controlled diabetes in selected regions of India : Results from the SMART India population-level diabetes screening study

enthalten in: Diabetic medicine : a journal of the British Diabetic Association | 2023

von Rajalakshmi, R. | Vasconcelos, J. | Prevost, A. | +37

4

Burden of undiagnosed and suboptimally controlled diabetes in selected regions of India : Results from the SMART India population‐level diabetes screening study

enthalten in: Diabetic Medicine | 2023

von Rajalakshmi, R. | Vasconcelos, J. | Prevost, A. | +9

5

Prevalence of diabetic retinopathy in India stratified by known and undiagnosed diabetes, urban-rural locations, and socioeconomic indices : results from the SMART India population-based cross-sectional screening study

enthalten in: The Lancet. Global health | 2022

von Raman, R. | Vasconcelos, J. | Rajalakshmi, R. | +35

ErratumIn: Lancet Glob Health. 2022 Nov 21;:. - PMID 36423645

6

Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double blind, parallel group placebo-controlled clinical trial Protocol

enthalten in: ResearchSquare.com | 2022

von Al-Laith, M. | Jasenecova, M. | Abraham, S. | +27

7

Arthritis Prevention in the Pre-Clinical Phase of RA with Abatacept (the APIPPRA Study): A Multi-Centre, Randomised, Double Blind, Parallel Group Placebo-Controlled Clinical Trial

enthalten in: ResearchSquare.com | 2022

von Al-Laith, M. | Jasenecova, M. | Abraham, S. | +27

8

Correction to : Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study

enthalten in: PharmacoEconomics | 2021

von Pennington, B. | Alshreef, A. | Flight, L. | +12

ErratumFor: Pharmacoeconomics. 2021 Aug;39(8):913-927. - PMID 33900585

9

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion : The LEAVO Study

enthalten in: PharmacoEconomics | 2021

von Pennington, B. | Alshreef, A. | Flight, L. | +12

ErratumIn: Pharmacoeconomics. 2021 Jun 19;:. - PMID 34148190

10

Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study

enthalten in: PharmacoEconomics | 2021

von Pennington, B. | Alshreef, A. | Flight, L. | +12